@kellycaspersonmd's testosterone claims, fact-checked

What did @kellycaspersonmd actually say?

Dr. Casperson makes two core arguments here. First, that perimenopausal women can benefit from testosterone alone, without estrogen or progesterone, for symptoms like fatigue, brain fog, and body composition changes. Second, she pushes back on the conventional view that testosterone stays relatively stable after menopause, saying "not in my experience" and suggesting many perimenopausal women already have low testosterone before estrogen drops sharply.

She also briefly addresses breast cancer survivors, noting she starts them on a "standard dose" and titrates carefully. This is a meaningful clinical point, not a throwaway comment, because testosterone in breast cancer survivors is one of the more contested areas in women's hormonal health. She's not claiming testosterone cures anything, which is worth noting upfront.

Does the science back this up?

Partly, but it's more complicated than the video suggests. The evidence for testosterone improving libido in postmenopausal women is actually reasonably strong. Davis et al. (2019, The Lancet Diabetes and Endocrinology) conducted a systematic review and meta-analysis of 36 trials and found testosterone significantly improved sexual function in postmenopausal women. That part of the argument has real backing.

The claim that testosterone can fall early in perimenopause, before estrogen, is more debated. The Penn Ovarian Aging Study (Freeman et al., 2007, Human Reproduction) tracked hormone levels longitudinally and found testosterone decline is gradual and variable across the menopausal transition, not a cliff drop like estrogen. Some women do show low testosterone in early perimenopause. But the idea that the conventional graph is simply wrong overstates the heterogeneity in the data.

On breast cancer survivors, a 2021 pilot study by Glaser et al. (Maturitas) suggested subcutaneous testosterone may not increase breast cancer recurrence risk, but sample sizes were small and follow-up limited. This is not settled science.

What did they get wrong (or right)?

She gets credit for one thing most social media hormone content gets wrong: she explicitly says testosterone is "not all about sexual function" and frames it around quality of life and body composition. That framing is consistent with the literature. Davis et al. (2019) documented effects on wellbeing beyond libido, though those secondary outcomes had wider confidence intervals.

Where she oversimplifies: the graph she dismisses, showing testosterone declining gradually rather than sharply, is actually what most population-level data show. Her clinical observation that many of her patients have low testosterone in early perimenopause is plausible and may reflect real selection bias in who seeks care, but it is not the same as saying the population-level data is wrong. Clinical experience is not epidemiology, and conflating the two is a common error in hormone content.

Her confidence about prescribing testosterone to breast cancer survivors without more caveats is the most medically sensitive moment in this clip. The Endocrine Society and NAMS both stop short of recommending testosterone as routine therapy in breast cancer survivors due to insufficient long-term safety data.

What should you actually know?

Testosterone therapy for women is not FDA-approved in the United States for any indication, full stop. The products used are either compounded or used off-label. That is not automatically a reason to avoid it, but it means dosing, formulation, and monitoring are not standardized the way they are for male testosterone therapy.

If you are perimenopausal and experiencing fatigue, brain fog, or changes in body composition, low testosterone is one possible contributor among several. Thyroid dysfunction, iron deficiency, sleep disorders, and mood conditions can produce identical symptom profiles. Testing total and free testosterone before treatment matters, but reference ranges for women are poorly validated, which complicates interpretation.

For breast cancer survivors specifically: talk to your oncologist before starting any hormone, including testosterone. Aromatization of testosterone to estrogen is a real physiological process that is not eliminated by using testosterone instead of estrogen directly. This is not a reason to never use it, but it is a reason to have a more detailed conversation than a podcast clip allows.